Ethinyl estradiol/norethindrone

Limits on what this shows

• Negative/null findings: None located in this review; only the single animal study was identified despite multiple search phrasings across PubMed and Crossref.
• At-risk subgroups: Not established; no human data located.

Regulatory status

Not addressed in the labels reviewed.

Population evidence

Fuller et al. 2022 (J Physiol), "Oral combined contraceptives induce liver mitochondrial reactive oxygen species and whole-body metabolic adaptations in female mice." Full text was blocked (403/429) in this review; the specific hormone doses and progestin identity used in the mouse model could not be confirmed. This is Tier B (animal, mechanistic), not Tier A, and is not confirmed drug-specific for norethindrone.

Mechanism

Increased hepatic mitochondrial reactive oxygen species production, reported alongside reduced physical activity and energy expenditure in the same animals, described by the study authors as a whole-body metabolic adaptation to combined-contraceptive exposure.

Counter-evidence held on record

None located. This is a single animal study; species translation to humans is not established, and this is explicitly disclosed as a limitation rather than extrapolated into a human claim.

Limits on what this shows

• Negative/null findings: None specifically located; the human studies located are themselves weak/underpowered rather than clearly null, which is disclosed as a limitation of the available evidence rather than a confirmed absence of effect.
• At-risk subgroups: Possible interaction with obesity per Aitazaz 2020, though that study's design (mixed COC/injectable cohort) limits confidence in this specific subgroup claim for ethinyl estradiol/norethindrone.

Regulatory status

Not addressed in the labels reviewed.

Population evidence

Aitazaz et al. 2020 (J Aziz Fatimah Med Dent Coll), n=31 women using combined pills or progestin injections (mixed cohort, not COC-only): SOD and MDA levels significantly higher in an obese subgroup versus non-obese, confounded by obesity status. Khan et al. 2022 (Pak J Health Sci), n=84 (60 OC users vs 24 controls, female athletes): total antioxidant capacity reported as "significantly affected," hemoglobin approximately 0.27 g/dL higher and total serum protein approximately 0.13 g/dL lower in users, but no p-values were retrievable from the abstract and the specific OC formulation was not named. Fuller et al. 2022 (mouse, see Mitochondrial burden entry) found increased hepatic mitochondrial ROS.

Mechanism

Not firmly established in humans from the sources reviewed; the mouse data point to mitochondrial ROS overproduction in liver tissue specifically.

Counter-evidence held on record

Both human studies located are small (n=31, n=84), of uncertain rigor (missing statistics in the accessible abstract for Khan 2022; mixed contraceptive-method cohort in Aitazaz 2020), and neither confirms the drug's specific progestin. Graded yellow to reflect real but weak and inconsistent evidence.

Limits on what this shows

• Negative/null findings: Crews, Taper & Ritchey 1980 (Am J Clin Nutr): no significant metabolic balance alterations for copper, i.e., intake-versus-excretion balance was not clearly shifted even though serum/ceruloplasmin levels rise in other studies, consistent with a redistribution/carrier-protein effect rather than true net accretion.
• At-risk subgroups: Women with Wilson disease or other copper-handling disorders should have this pattern considered by their prescriber; not a general population risk at the magnitudes reported.

Regulatory status

Not addressed directly, but consistent with the label-documented estrogen-driven binding-globulin/transport-protein induction pattern (thyroid-binding globulin, sex-hormone-binding globulin, corticoid-binding globulin).

Population evidence

Prema, Ramalakshmi & Babu 1980 (Fertil Steril): serum copper increased within 10 days of starting a combined estrogen-progestogen formulation. Hinks, Clayton & Lloyd 1983 (J Clin Pathol): increased plasma and whole-blood copper in OC users. Schenker et al. 1971 (Fertil Steril) reported serum copper and zinc levels in OC users, direction consistent with increase. King, Reynolds & Margen 1978 (Am J Clin Nutr), n=22: copper absorption measured at 57% during OC use. None of these studies' progestin was confirmed as norethindrone specifically in this review; graded as class-level (Tier C/B).

Mechanism

Estrogen induces hepatic ceruloplasmin (a copper-binding oxidase) synthesis, raising total circulating copper without necessarily reflecting tissue copper accumulation. This is the same hepatic-protein-induction mechanism family as the label-documented globulin increases.

Counter-evidence held on record

Crews et al. 1980 found no significant copper balance alteration despite the serum-level increases reported elsewhere, suggesting a carrier-protein/redistribution explanation rather than true accretion in most users. Framing caution, per Hard Rule 5: this is an excess/retention finding. It must never be presented as a deficiency, and copper supplementation is not supported and could be a hazard in copper-sensitive individuals, not a remedy.

Limits on what this shows

• Negative/null findings: Keller 2020 is a cross-sectional comparison (OC users vs non-users), not a randomized or longitudinal design; this is an active-comparator-adjacent limitation, and selection effects (e.g., differences in exercise history or baseline iron status between women who choose OC use and those who do not) cannot be excluded from the abstract-level data reviewed.
• At-risk subgroups: Women with hereditary hemochromatosis or other iron-overload conditions should have this retention-adjacent pattern considered by their prescriber.

Regulatory status

Certain branded formulations of this drug class (e.g., Loestrin Fe) include ferrous fumarate tablets during the placebo week; the label states explicitly that these "are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose," directly rebutting any inference that the manufacturer added iron because the hormonal component depletes it.

Population evidence

Larsson, Milsom, Lindstedt & Rybo 1992 (Contraception), "The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status"; full text could not be opened in this review, progestin not confirmed as norethindrone, treated as Tier C. Keller, Harrison & Lalande 2020 (Med Sci Sports Exerc), "Impact of Menstrual Blood Loss and Oral Contraceptive Use on Oxygen-carrying Capacity": oral contraceptive use was associated with 12% higher hemoglobin mass normalized to body weight versus non-users; full text was paywalled (402 error) in this review, so design details (sample size, statistics) could not be independently confirmed beyond this reported figure.

Mechanism

Named and well-established: combined oral contraceptives suppress endometrial proliferation and reduce menstrual blood loss, which reduces iron loss over time compared with normal menstrual cycling.

Counter-evidence held on record

Keller 2020 is cross-sectional, not causal-design; confounding by exercise history/baseline iron status is a plausible competing explanation for part of the effect size, per the active-comparator caution in the evidence-retrieval protocol. Framing caution, per Hard Rule 5: this is a protective, not depleting, direction. Iron supplementation is not supported by this finding for typical users and is unnecessary; the "Fe" in some brand names reflects a placebo-week administration convenience, not a therapeutic response to drug-induced depletion (see label statement above).

Limits on what this shows

• Negative/null findings: Hua et al.'s primary finding is itself a null result for diversity/composition (n=10, small); this is the strongest and most direct available evidence located and is reported as such rather than omitted.
• At-risk subgroups: Not established; no subgroup with clinically meaningful microbiome disruption was identified in the sources reviewed.

Regulatory status

Not addressed in the labels reviewed.

Population evidence

Hua et al. 2022 (J Med Microbiol), longitudinal cohort of 10 healthy women sampled before OC initiation and at 1 and 6 months after: no changes in diversity or composition of the gut microbiome following OC initiation; age explained 9.9% of microbial community variance versus 2.7% for time-since-initiation. Mihajlovic et al. 2021 (Environ Microbiol), "Combined hormonal contraceptives are associated with minor changes in composition and diversity in gut microbiota of healthy women"; full abstract could not be retrieved in this review (bot-verification block), title alone used. Neither study confirmed norethindrone as the specific progestin.

Mechanism

Hua et al. report that despite stable overall diversity, relative abundance of biosynthesis pathways for peptidoglycan, several amino acids (lysine, threonine, methionine, tryptophan), and the NAD salvage pathway increased after OC initiation, and that estradiol and sex-hormone-binding globulin correlated positively with the flavonoid-degrading species Eubacterium ramulus. This is a functional/metabolic-pathway effect, not a dysbiosis or diversity-loss effect.

Counter-evidence held on record

Hua et al. 2022 is itself a null/near-null finding for overall diversity and composition (the primary measures a "gut dysbiosis" claim would invoke), even though the same small study found small functional-pathway shifts. Sample size is small (n=10) and should not be over-read as definitive reassurance either.

Limits on what this shows

• Negative/null findings: Cross-sectional design; selection effects (e.g., differing exercise history between OC users and non-users in this specific cohort) are a plausible partial explanation and cannot be excluded from the abstract-level data available.
• At-risk subgroups: None identified as at-risk from this specific finding; it is a favorable finding, not a risk.

Regulatory status

Not addressed in the labels reviewed.

Population evidence

Keller, Harrison & Lalande 2020 (Med Sci Sports Exerc), "Impact of Menstrual Blood Loss and Oral Contraceptive Use on Oxygen-carrying Capacity": hemoglobin mass 12% higher in OC users versus non-users, normalized to body weight; full text was paywalled (402 error) in this review, limiting confirmation of sample size, statistical testing, and exact progestin.

Mechanism

Same mechanism as the Iron entry above: reduced menstrual blood loss on combined OC therapy reduces cumulative iron loss, supporting higher hemoglobin mass and red-cell mass over time. This entry and the Iron entry share this single underlying mechanism/source pairing; see Overlap map.

Counter-evidence held on record

Cross-sectional, active-comparator-adjacent design; cannot fully exclude selection/confounding by exercise history or baseline hematologic status between groups. Framing caution, per Hard Rule 5: this is a protective, reverse-direction finding, not an oxygen-delivery deficiency. It must not be reworded as evidence that this drug impairs oxygen delivery.

Limits on what this shows

• Negative/null findings: Massart et al. themselves found no significant difference in ATP synthesis during apoptosis between estradiol-treated and control cells, a direct null result for ATP output specifically, even though ATP synthase catalytic activity was reduced; this is disclosed as a genuine complicating finding rather than omitted. Chiara et al. did not measure ATP directly, found no significant nitric oxide change, and describe their own findings as preliminary, from a single cell line, at a single 48-hour timepoint, with named assay-specificity and normalization limitations.
• At-risk subgroups: Not established for this drug in any human population; both sources are in vitro cell-model studies (osteoclast-lineage and neuroblastoma lines) with uncertain relevance to whole-body energy metabolism in combined-OC users.

Regulatory status

Not addressed in the labels reviewed; no ATP-production or cellular-energy claim appears in the Balziva or Loestrin Fe labeling.

Population evidence

Massart, Paolini, Piscitelli, Brandi & Solaini 2002 (Gynecol Endocrinol), an in vitro study in osteoclastic cells: 17-beta-estradiol inhibited mitochondrial ATP synthase activity rapidly and dose-dependently, with roughly half-maximal inhibition near 30 nmol/L and activity reduced to about 15% of baseline at 100 nmol/L; uncoupled respiration was unaffected, indicating the effect targeted the synthase specifically rather than general mitochondrial poisoning. This study uses 17-beta-estradiol, not ethinyl estradiol, and an osteoclast model unrelated to this drug's typical target tissues, so it is Tier C for this drug (related-hormone, class-adjacent mechanism, this medication not in the model). Chiara, Allegra, Agar, Abbadessa & De Francia 2026 (Biomedicines), a preliminary in vitro study in SH-SY5Y neuroblastoma cells exposed to ethinylestradiol combined with dienogest (a different progestin than norethindrone) at clinically informed concentrations: found a significant reduction in mitochondrial membrane potential (JC-1 red/green ratio, Welch's ANOVA W(4,16)=15.610, p<0.001) and a significant increase in reactive oxygen species (Welch's ANOVA W(4,15)=22.380, p<0.001) versus vehicle control at 48 hours, with effects modulated by simulated follicular- versus luteal-phase hormonal background; nitric oxide (DAF-FM) did not differ significantly. This study uses the same ethinyl estradiol component as this drug but a different progestin, and measured membrane potential and ROS, not ATP content or synthesis directly, so it is Tier C for this drug and adjacent rather than direct evidence for this specific category.

Mechanism

Massart et al. propose a rapid, non-genomic mechanism in which estradiol directly modulates the mitochondrial F0F1 ATP synthase complex, independent of classical nuclear estrogen-receptor transcription. Chiara et al. propose that combined-OC steroids and the surrounding sex-hormone milieu jointly perturb mitochondrial membrane potential and redox state, consistent with, but not proof of, reduced oxidative-phosphorylation capacity; membrane potential is the driving force for ATP synthase but a fall in it does not by itself confirm reduced ATP output.

Counter-evidence held on record

This category was left ungraded in the prior version of this dossier because of session-wide 429 rate-limiting on PubMed, Crossref, Europe PMC, and Semantic Scholar plus an exhausted WebSearch budget. This revision re-ran the search with a dedicated tool budget across the same four channels plus OpenAlex. PubMed remained blocked by an un-completable reCAPTCHA challenge on every attempt in this revision, and Europe PMC and Semantic Scholar returned persistent HTTP 429 responses throughout this session despite repeated, spaced attempts across many query phrasings; this confirms those three channels were a genuine access limitation at the time of both the original review and this revision, not a one-off batch artifact. Crossref remained usable throughout this revision and was the channel that surfaced both sources above; OpenAlex, not tried in the original review, was added as a working channel and used to retrieve the full abstracts quoted above. The estradiol concentrations shown to inhibit ATP synthase in Massart et al. (30 to 100 nmol/L) are far above the sub-nanomolar to low-nanomolar concentrations of circulating estradiol or ethinyl estradiol typically seen in combined-OC users, so direct translation to whole-body ATP production at therapeutic OC dosing is not established by this source. No drug-specific (norethindrone) or exact-formulation study measuring ATP synthesis, ATP content, or mitochondrial ATP output was located in this revision despite the additional access. Framing caution: both sources are in vitro, use a different progestin or a related but not identical estrogen, and neither measures whole-body, muscle, or liver ATP output in humans. This is mechanistic plausibility for the estrogen-driven effect family already documented elsewhere in this dossier, not evidence of a clinical energy deficit, and should never be presented to consumers as "birth control depletes your ATP" or "causes chronic fatigue."